Purchase disclosed
Thomas Patrick Kelly
Chief Financial Officer
Common Shares
- Reported value
- $559.74K
- Reported price
- $37.316 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Xenon Pharmaceuticals Inc.
Last 30 daysInsiders bought $1.68M · 2 buyers, led by Ian Mortimer (CEO) with $1.12M. No qualifying insider sales.
Chief Financial Officer
Common Shares
PRESIDENT & CEO
Common Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chief Financial Officer | Common SharesPurchase | 15,000$37.32 / share | $559.74K | Sep 30Filed Oct 1 · 1d later | SEC filing |
| PRESIDENT & CEO | Common SharesPurchase | 30,000$37.38 / share | $1.12M | Sep 30Filed Oct 1 · 1d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$1,681,140 of common-equity purchase value after transaction-age decay across 180 days.
2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
2 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.